Expression of Bcl-xL and Mcl-1 in the nonmelanoma skin cancers of renal transplant recipients

Simple item page
dc.contributor.authorBurke, M.
dc.contributor.authorMorais, C.
dc.contributor.authorOliver, K.
dc.contributor.authorLambie, D.
dc.contributor.authorGobe, G.
dc.contributor.authorCarroll, R.
dc.contributor.authorStaatz, C.
dc.contributor.authorSinnya, S.
dc.contributor.authorSoyer, H.
dc.contributor.authorWinterford, C.
dc.contributor.authorHaass, N.
dc.contributor.authorCampbell, S.
dc.contributor.authorIsbel, N.
dc.date.issued2015
dc.description.abstractObjectives: This study aims to investigate how immunosuppression influences the protein expression of antiapoptotic members of the Bcl-2 family—namely, Bcl-xL and Mcl-1—in nonmelanoma skin cancer (NMSC) and the peritumoral epidermis of renal transplant recipients. Methods: NMSC and peritumoral epidermis protein expression of Bcl-xL and Mcl-1 were assessed by immunohistochemistry in renal transplant recipients receiving tacrolimus or sirolimus and the general population not receiving immunosuppression. Results: NMSC from renal transplant recipients compared with patients not receiving immunosuppressant medications had a reduced Bcl-xL expression intensity (P = .042). Mcl-1 expression intensity in NMSC was decreased in tacrolimus-treated patients compared with sirolimus-treated patients and the nonimmunosuppressed population (P = .024). Bcl-xL expression intensity was increased in peritumoral epidermis compared with NMSC (P = .002). Conclusions: It was shown for the first time that Bcl-xL and Mcl-1 expression are widespread in the peritumoral epidermis and NMSC of renal transplant recipients. Importantly in NMSC, Bcl-xL expression was reduced with immunosuppression exposure, and Mcl-1 expression was reduced in tacrolimus-treated compared with sirolimustreated patients.
dc.description.statementofresponsibilityMichael T. Burke, Christudas Morais, Kimberley A. Oliver, Duncan L. J. Lambie, Glenda C. Gobe, Robert P. Carroll, Christine E. Staatz, Sudipta Sinnya, H. Peter Soyer, Clay Winterford, Nikolas K. Haass, Scott B. Campbell and Nicole M. Isbel
dc.identifier.citationAmerican Journal of Clinical Pathology, 2015; 143(4):514-526
dc.identifier.doi10.1309/AJCPQNB5WA3PLQBK
dc.identifier.issn0002-9173
dc.identifier.issn1943-7722
dc.identifier.orcidCarroll, R. [0000-0002-6238-026X]
dc.identifier.urihttp://hdl.handle.net/2440/90731
dc.language.isoen
dc.publisherLippincott, Williams & Wilkins
dc.rights© 2015 by The American Society for Clinical Pathology
dc.source.urihttps://doi.org/10.1309/ajcpqnb5wa3plqbk
dc.subjectHumans
dc.subjectCarcinoma, Basal Cell
dc.subjectCarcinoma, Squamous Cell
dc.subjectSkin Neoplasms
dc.subjectSirolimus
dc.subjectTacrolimus
dc.subjectImmunosuppressive Agents
dc.subjectKidney Transplantation
dc.subjectImmunohistochemistry
dc.subjectMitosis
dc.subjectApoptosis
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.subjectbcl-X Protein
dc.subjectMyeloid Cell Leukemia Sequence 1 Protein
dc.subjectTransplant Recipients
dc.titleExpression of Bcl-xL and Mcl-1 in the nonmelanoma skin cancers of renal transplant recipients
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications